BROOKLYN, N.Y - Tuesday, September 16th 2014 [ME NewsWire]
(BUSINESS WIRE)-- Endocrine Technology, L.L.C. is a New York-based biotechnology company detailed at www.etbondusa.com. Kumar Shah, M.D., President of the company, brings the most advanced technology to solve the ebola crisis. There is an enormous humanitarian and scientific need for the masses to get united to fight the ebola crisis.
There is a growing scientific consensus that:
a. An expedient solution to the crisis must be found in an available drug.
b. Evidence-based scientific data should be unearthed that is deeply buried in medical literature.
c. The potential solution must be in keeping with cutting edge advances in genomics and fundamentals of immunology.
“It is expected that meeting the above criteria will give confidence and galvanize global cooperation to advance such technology to save lives expediently. The mortality rate may surge to 1.2 million in the coming year,” Dr. Kumar Shah stated.
Endocrine Technology, LLC and its dedicated “ETBOND Team members” have advanced such a technology. www.etbondusa.com provides links to patent application, references, interim drug draft label and slide presentations.
The patent application details a novel immune modulation drug. During therapy it down regulates inflammatory and bleeding responses seen in ebola infected patients by inhibiting serine proteases. During the recovery phase the drug stimulates host immune responses to kill ebola. The later strategy can be extended to asymptomatic patients to cure ebola infection. The modeling of three-dimensional interaction of ebola with host and its immune system suggest that ebola is a highly charged particle that activates proteases and can be effectively neutralized by ET 007, a drug that is a nano formulated version of a globally available drug. It is safe and effective to initiate global efforts to treat and eradicate the ebola crisis.
Kumar Shah, M.D. is the USA trained Board Certified Physician, President and Patent developer. He has 20 plus years of medical and biotechnology industry experience. He is in charge of global Medical and Technology Consulting services for ebola. He is assisted by a dedicated ETBOND Team.
Contacts
Endocrine Technology, L.L.C.
Att. Kumar Shah, M.D., 718-222-1065
President
etbond@gmail.com
www.etbondusa.com
Permalink: http://www.me-newswire.net/news/12099/en